Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPPER: Ultra-short DAA Prophylaxis in HCV+ Kidney Transplant
NCT03249194Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by Virginia Commonwealth University. Primary endpoints: Sustained Virologic Response at 12 weeks, Graft Survival at 1 year and 1 more. Started Aug 2017; status: completed.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03249194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249194.